Another new anti-HIV drug in the non-nucleoside reverse transcriptase inhibitor (NNRTI) class that has shown promise is TMC125. You don’t mention this drug, but it has been shown in trial studies to have replaced five drugs for drug-resistant patients, it produces a large drop in viral load, and it has been shown to have very mild side affects. I found this particularly interesting because the current protease inhibitors and some NNRTI drugs are known to cause abnormal redistribution of body fat and potentially fatal liver toxicities.
G. David Baca Colorado Springs, Colo.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.